Warrington KH Jr, Herzog RW. Treatment of human disease by adeno-associated viral gene transfer. Hum Genet. 2006;119:571–603.

Article  CAS  PubMed  Google Scholar 

Nathwani AC, Davidoff AM, Tuddenham EGD. Gene therapy for hemophilia. Hematol/Oncol Clin North Am. 2017;31:853–68.

Article  PubMed  Google Scholar 

Carvalho LS, Vandenberghe LH. Promising and delivering gene therapies for vision loss. Vis Res. 2015;111:124–33.

Article  PubMed  Google Scholar 

Hocquemiller M, Giersch L, Audrain M, Parker S, Cartier N. Adeno-associated virus-based gene therapy for CNS diseases. Hum Gene Ther. 2016;27:478–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hudry E, Aihara F, Meseck E, Mansfield K, McElroy C, Chand D, et al. Liver injury in cynomolgus monkeys following intravenous and intrathecal scAAV9 gene therapy delivery. Mol Therapy. 2023. https://doi.org/10.1016/j.ymthe.2023.07.020.

Shen W, Liu S, Ou L. rAAV immunogenicity, toxicity, and durability in 255 clinical trials: a meta-analysis. Front Immunol. 2022;13:1001263.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shieh PB, Bönnemann CG, Müller-Felber W, Blaschek A, Dowling JJ, Kuntz NL, et al. Re: ‘Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy’ by Wilson and Flotte. Hum Gene Ther. 2020;31:787.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ge Y, Powell S, Van Roey M, McArthur JG. Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX. Blood. 2001;97:3733–7.

Article  CAS  PubMed  Google Scholar 

Cordier L, Gao GP, Hack AA, McNally EM, Wilson JM, Chirmule N, et al. Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. Hum Gene Ther. 2001;12:205–15.

Article  CAS  PubMed  Google Scholar 

Fields PA, Arruda VR, Armstrong E, Chu K, Mingozzi F, Hagstrom JN, et al. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. Mol Ther: J Am Soc Gene Ther. 2001;4:201–10.

Article  CAS  Google Scholar 

Franco LM, Sun B, Yang X, Bird A, Zhang H, Schneider A, et al. Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. Mol Ther: J Am Soc Gene Ther. 2005;12:876–84.

Article  CAS  Google Scholar 

Wang L, Dobrzynski E, Schlachterman A, Cao O, Herzog RW. Systemic protein delivery by muscle-gene transfer is limited by a local immune response. Blood. 2005;105:4226–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sarukhan A, Camugli S, Gjata B, von Boehmer H, Danos O, Jooss K. Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors. J Virol. 2001;75:269–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bell P, Gao G, Haskins ME, Wang L, Sleeper M, Wang H, et al. Evaluation of adeno-associated viral vectors for liver-directed gene transfer in dogs. Hum Gene Ther. 2011;22:985–97.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Calne RY, Sells RA, Pena JR, Davis DR, Millard PR, Herbertson BM, et al. Induction of immunological tolerance by porcine liver allografts. Nature. 1969;223:472–6.

Article  CAS  PubMed  Google Scholar 

Girlanda R, Rela M, Williams R, O’Grady JG, Heaton ND. Long-term outcome of immunosuppression withdrawal after liver transplantation. Transplant Proc. 2005;37:1708–9.

Article  CAS  PubMed  Google Scholar 

Knechtle SJ, Kwun J. Unique aspects of rejection and tolerance in liver transplantation. Semin Liver Dis. 2009;29:91–101.

Article  PubMed  Google Scholar 

Creput C, Durrbach A, Samuel D, Eschwege P, Amor M, Kriaa F, et al. Incidence of renal and liver rejection and patient survival rate following combined liver and kidney transplantation. Am J Transplant: Off J Am Soc Transplant Am Soc Transpl Surg. 2003;3:348–56.

Article  Google Scholar 

Dai H, Zheng Y, Thomson AW, Rogers NM. Transplant tolerance induction: insights from the liver. Front Immunol. 2020;11:1044.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wieland D, Hofmann M, Thimme R. Overcoming CD8+ T-cell exhaustion in viral hepatitis: lessons from the mouse model and clinical perspectives. Dig Dis. 2017;35:334–8.

Article  PubMed  Google Scholar 

Germanidis G, Argentou N, Hytiroglou P, Vassiliadis T, Patsiaoura K, Germenis AE, et al. Liver FOXP3 and PD1/PDL1 expression is down-regulated in chronic HBV hepatitis on maintained remission related to the degree of inflammation. Front Immunol. 2013;4:207.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cho H, Kang H, Lee HH, Kim CW. Programmed cell death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) in viral hepatitis. Int J Mol Sci. 2017;18:E1517.

Article  Google Scholar 

LoDuca PA, Hoffman BE, Herzog RW. Hepatic gene transfer as a means of tolerance induction to transgene products. Curr Gene Ther. 2009;9:104–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mingozzi F, Hasbrouck NC, Basner-Tschakarjan E, Edmonson SA, Hui DJ, Sabatino DE, et al. Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood. 2007;110:2334–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cooper M, Nayak S, Hoffman BE, Terhorst C, Cao O, Herzog RW. Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer. Hum Gene Ther. 2009;20:767–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Perrin GQ, Zolotukhin I, Sherman A, Biswas M, de Jong YP, Terhorst C, et al. Dynamics of antigen presentation to transgene product-specific CD4(+) T cells and of Treg induction upon hepatic AAV gene transfer. Mol Ther Methods Clin Dev. 2016;3:16083.

Article  PubMed  PubMed Central  Google Scholar 

Zhang P, Sun B, Osada T, Rodriguiz R, Yang XY, Luo X, et al. Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease. Hum Gene Ther. 2012;23:460–72.

Article  PubMed  PubMed Central  Google Scholar 

Yiu WH, Lee YM, Peng WT, Pan CJ, Mead PA, Mansfield BC, et al. Complete normalization of hepatic G6PC deficiency in murine glycogen storage disease type Ia using gene therapy. Mol Ther: J Am Soc Gene Ther. 2010;18:1076–84.

Article  CAS  Google Scholar 

Han S-O, Ronzitti G, Arnson B, Leborgne C, Li S, Mingozzi F, et al. Erratum: low-dose liver-targeted gene therapy for pompe disease enhances therapeutic efficacy of ERT via immune tolerance induction. Mol Ther Methods Clin Dev. 2019;13:431.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao G, Wang Q, Calcedo R, Mays L, Bell P, Wang L, et al. Adeno-associated virus-mediated gene transfer to nonhuman primate liver can elicit destructive transgene-specific T cell responses. Hum Gene Ther. 2009;20:930–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Toromanoff A, Chérel Y, Guilbaud M, Penaud-Budloo M, Snyder RO, Haskins ME, et al. Safety and efficacy of regional intravenous (RI) versus intramuscular (IM) delivery of rAAV1 and rAAV8 to nonhuman primate skeletal muscle. Mol Ther. 2008;16:1291–9.

Article  CAS  PubMed